Startup profile · funding coverage
Nanopath funding, valuation and investors
Amplification-free plasmonic molecular diagnostics aiming for 15-minute women's-health testing.
Verified company research · funding, investors and latest developments
Keep track of Nanopath
Save this profile to your VCT watchlist for a quick return.
Funding, valuation & investors
Answer-first snapshotLatest funding
Series B financing package (includes $2M non-dilutive grants)
$25M total package (~$23M non-grant portion inferred) · November 10, 2026
Latest known valuation
Undisclosed
Series B financing package (includes $2M non-dilutive grants) · November 10, 2026
Total disclosed equity funding
$14M
Excludes debt, grants, acquisitions, secondaries, and IPO proceeds.
Current status
private
series b · Cambridge, Massachusetts, USA
Investors in latest funding
Lead: Norwest , Medtech Convergence Fund (SV Health Investors)
Other: Labcorp Venture Fund , Elderberry Ventures , GingerBread Capital , Alumni Ventures
Overview
Cambridge, Massachusetts diagnostics developer spun out of Dartmouth research, founded around 2019–2020. Its optical biosensing platform is designed to detect pathogen DNA and RNA directly in single-visit near-patient testing without PCR amplification.
The $25M November 2026 financing package includes $2M in grants and is co-led by Norwest and SV Health Investors' Medtech Convergence Fund; FDA clearance, clinical performance at scale, revenue and test pricing remain undisclosed.
Why Nanopath is interesting
November 10, 2026 financing is $25M including $2M non-dilutive grant capital, not $25M equity. Its first vaginitis assay is still under development and not FDA-cleared; the funding supports a proposed 510(k) clinical study and manufacturing readiness.
Product & use cases
Prospective, not commercial, clinician journey: (1) obtain patient sample during a visit; (2) introduce it into Nanopath's intended single-use cartridge; (3) instrument optically senses targeted nucleic acids without amplification; (4) retrieve proposed ~15-minute molecular result; (5) clinician interprets findings in clinical context. Nanopath's vaginitis test has not been FDA-cleared; study initiation is planned. The company has not disclosed per-test pricing, measured real-world accuracy, installed base, nor commercial availability. This is an illustrative future workflow, not hands-on testing or a validated deployed service.
- Planned point-of-care vaginitis testing; pre-clearance and clinical study pending.
- Potential later tests for UTIs and STIs; indications are development plans, not approved assays.
- Research/development partners evaluating amplification-free plasmonic biosensor assays in clinical collaborations.
Key facts
- Nov 10, 2026 issuer describes $25M Series B financing package including $2M non-dilutive grants; approximately $23M is implied non-grant finance, but the precise share terms are not public.
- August 9, 2022 $10M Series A led by Norwest and SV Health Investors' Medtech Convergence Fund.
- May 21, 2024 separate NIH/NSF SBIR grants $4M, not venture equity. The 2026 company-reported more-than-$46M lifetime financing mixes financing types and cannot be used as equity-only total.
- Lead vaginitis assay explicitly not FDA cleared or approved as of Nov 10, 2026, despite work toward a 510(k) study.
Funding history (newest first)
Series B financing package (includes $2M non-dilutive grants)
2026-11-10 $25M total package (~$23M non-grant portion inferred) Valuation: Undisclosed- Norwest (lead)
- Medtech Convergence Fund (SV Health Investors) (lead)
- Labcorp Venture Fund (participant)
- Elderberry Ventures (participant)
- GingerBread Capital (participant)
- Alumni Ventures (participant)
Source: Read source · prnewswire.com
NIH/NSF SBIR grants (non-dilutive, NOT Series A extension)
2024-05-21 $4M Valuation: Not applicableSource: Read source · prnewswire.com
Series A
2022-08-09 $10M Valuation: Undisclosed- Norwest Venture Partners (lead)
- Medtech Convergence Fund (SV Health Investors) (lead)
- GingerBread Capital (participant)
- Green D Ventures (participant)
Source: Read source · prnewswire.com
Competitive landscape
Edge: Company aims to avoid PCR nucleic-acid amplification, reducing workflow steps and reagents versus many established molecular tests. Analytical sensitivity, regulatory outcomes and commercial unit economics remain unproven publicly.
Regulatory milestone and actual hospital adoption are the key differentiation gates. Breakthrough-device designations for other assays, if any, are not substitute FDA clearance for the vaginitis assay. The $25M mixed package must not be counted as pure equity, while the earlier $4M NIH/NSF grants are not another VC round.
-
Cepheid GeneXpert alternative
Established molecular diagnostic testing ecosystem using amplification; compare indication and clearance, footprint and per-test economics.
-
Roche cobas Liat alternative
Molecular near-patient testing platform; assay menus and approved indications differ.
-
Visby Medical adjacent
Rapid molecular women's-health testing category; compare approved test indications, timing and real-world performance.
-
Traditional centralized PCR labs incumbent
Established accuracy and broad menus, but transportation and turnaround can extend time to treatment.
Market / IPO context
Editorial / static context — not a live quote.
FAQs about Nanopath
Practical answers founders, operators, and investors typically search for.
Last updated:
Editorial note: AI tools assisted with research, structure, or drafting. Venture Capital Tracker retains human editorial responsibility for factual accuracy, relevance, and source quality before publication.